Medical Devices Risk to Tackle Coronavirus

May 26, 2020 | (Online)
Webcast , Countries

Please join our first webcast, Medical Devices Risk to Tackle Coronavirus, as part of our series that will offer guidance to understand how to navigate and manage the potential risks that come with producing medical devices.

As COVID-19 developments increase at a rapid rate globally, the concern about the lack of life-saving equipment and other essential supplies to prevent the spread of the virus and care for the sick are also rapidly increasing.

More broadly, there is urgent need to escalate the manufacturing of a full range of medical devices, such as face masks, ventilators and test kits (self-administered, antibody tests). To help meet needs during this crisis, governments are now turning to the private sector for assistance, not just in physical manufacturing but also for capabilities in design, procurement, assembly, testing and shipping.

Schedule 4:00 p.m. – 4:45 p.m. BST (11 a.m. – 11:45 a.m. EST)

Register now.

Key Takeaways

Identifying supplier credibility:

  • Uncertainty over which suppliers can produce equipment of the right quality, at the right production volume, at the right time

  • Lack of understanding a new industry to work within (ie. retail to medical device industry) can create opportunity for credibility risk


  • Transport tracking options need to be validated to ensure the right shipments can move from factories to airports to distribution centers to health centers around the world, under the right conditions (e.g., temperature controlled for pharmaceutical products)

  • Exposure to risks in working within a new industry and new vendors

Third-party commercial representation: 

  • Corruption in the medical industry can range vastly from bribing a doctor to prescribe medicine irrespective of a health need, to a government employee facilitating the infiltration of substandard medicines into the distribution system for kickbacks

  • Global scramble for vital items has exposed the harsh realities of international politics and the limits of the freed market 


  • Thomas Hollobone, Associate Managing Director, Compliance Risk and Diligence,
    Kroll, a division of Duff & Phelps

  • Andreas Chrystomou, Managing Director, Valuation Services,
    Global Healthcare and Life Sciences Industry Leader, Duff & Phelps

  • Roeland Van Aelst, EMEA Lead Third Party Intermediary Ethics and Compliance, 
    Johnson & Johnson, Chairman, International Society of Healthcare, Ethics and Compliance Professionals (ETHICS), Chairman, MedTech Europe Code Committee

We look forward to your attendance. Click here to register for this webinar.

Compliance Risk and Diligence

The Kroll Investigations, Diligence and Compliance team partners with clients to anticipate, detect and manage regulatory and reputational risks associated with global ethics and compliance obligations.

Due Diligence Wizard Tool

Determine which due diligence product best fits your needs.

Compliance Program Consulting

Kroll is trusted by companies worldwide to help establish policies and programs aimed toward preventing fraud and complying with anti-money laundering (AML) and anti-bribery and corruption regulations.

AML Compliance Due Diligence

Kroll helps clients navigate the complexities of today’s regulatory environment through a broad suite of anti-money laundering compliance screening and due diligence offers.

Compliance Portal

Your Process. Our Technology.